Scientific EXPERT Act of 2025

This bill requires the FDA to take part in special meetings run by an outside organization called the Reagan-Udall Foundation to talk about how to develop treatments for rare diseases. These meetings must happen at least four times a year, each one focusing on a different rare disease, and they must include medical experts, drug companies, patient groups, and FDA staff. A steering committee would pick which diseases to discuss based on things like how much patients need new treatments and how many people are affected. After each meeting, a summary must be made public, and the FDA must say whether it used any input from these meetings when approving new drugs.

Your Vote